Analysis of whether Eslicarbazepine has been launched in China and its market supply situation

Eslicarbazepine (Eslicarbazepine) has not been officially launched in mainland China, nor has it been included in the national medical insurance directory. Therefore, domestic patients cannot legally obtain the drug through hospitals or pharmacies. Eslicarbazepine is a new type of anti-epileptic drug, mainly used to treat focal epileptic seizures. It can reduce abnormal discharges by stabilizing neuronal membrane potential, thereby reducing the frequency of epileptic seizures. Its pharmacological effects are relatively mild, and compared with traditional anti-epileptic drugs, it is better tolerated by patients and has relatively fewer side effects, including mild dizziness, drowsiness, indigestion, etc.

In the international market, the price of eslicarbazepine is relatively high. Taking 800mg per tablet and 30 tablets as an example, the average selling price is about 1230.99 US dollars, which is equivalent to about 8800 yuan in RMB. Actual patient out-of-pocket costs may be higher because cross-border purchases are involved, and customs duties, shipping charges, and overseas pharmacy markups may also be borne. This undoubtedly increases the financial burden for epilepsy patients who require long-term treatment. When patients consider purchasing drugs through formal overseas channels, they should fully understand the source, transportation method and shelf life of the drugs to ensure the safety and effectiveness of the drugs.

Since it is not yet on the market, eslicarbazepine is temporarily not eligible for medical insurance reimbursement in the country. In the future, if the drug is approved for marketing and undergoes medical insurance negotiation, it may be gradually included in the medical insurance catalog, thus reducing the financial pressure on patients. At the same time, clinicians and patients should also pay attention to domestic drug registration progress and policy developments, and obtain marketing and reimbursement information in a timely manner so as to rationally arrange treatment plans. Even if it is included in medical insurance in the future, a scientific medication plan must be formulated based on the patient's condition and doctor's recommendations.

In short, eslicarbazepine is still not on the market in China. Patients mainly rely on overseas formal channels to purchase it. It is expensive and cannot be reimbursed through medical insurance. Its efficacy and tolerability in the treatment of focal epilepsy have been internationally clinically verified. In the future, with the advancement of marketing and policies, patients may enjoy more convenient and economical medication methods, but before that, they need to fully evaluate their own economic affordability and medication safety to ensure that the treatment is scientific and reasonable.

Reference materials:https://www.drugs.com/